Expression of genes of glutathione transferase isoforms GSTP1-1, GSTA4-4, and GSTK1-1 in tumor cells during the formation of drug resistance to cisplatin

Bulletin of Experimental Biology and Medicine

Volumn 154, Issue 1, 2012, Pages 64-67

  Kalinina, E V ^a   Berozov, T T ^a   Shtil, A A ^b   Chernov, N N ^a   Glasunova, V A ^b   Novichkova, M D ^a   Nurmuradov, N K ^a  

^a PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

cisplatin; drug resistance of tumor cells; gene expression; glutathione S transferase isoforms

Indexed keywords

4 HYDROXYNONENAL; CISPLATIN; ETACRYNIC ACID; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A4 4; GLUTATHIONE TRANSFERASE K1 1; GLUTATHIONE TRANSFERASE P1 1; ISOENZYME; MESSENGER RNA; UNCLASSIFIED DRUG; GLUTATHIONE TRANSFERASE P1; GSTK1 PROTEIN, HUMAN; GSTP1 PROTEIN, HUMAN; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE-C4 SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER RESISTANCE; CELL PROTECTION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME SUBSTRATE; ERYTHROLEUKEMIA; GENE; GENE EXPRESSION; GSTA4 4 GENE; GSTK1 1 GENE; GSTP1 1 GENE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY ADENOCARCINOMA; PROTEIN FUNCTION; TUMOR CELL; ADENOCARCINOMA; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; OVARIAN NEOPLASMS;

MLCS; MLOWN;

EID: 84877131527     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-012-1876-4     Document Type: Article

References (15)

1. Y. Aniya and N. Imaizumi, Drug Metab. Rev., 43, No. 2, 292-299 (2011).
2. K. Berhane, M. Widersten, A. Engstrom, et al., Proc. Natl. Acad. Sci. USA, 91, No. 4, 1480-1484 (1994).
3. J. M. Curtis, P. A. Grimsrud, W. S. Wright, et al., Diabetes, 59, No. 5, 1132-1142 (2010).
4. F. Desmots, M. Rissel, C. Pigeon, et al., Free Radic. Biol. Med., 32, No. 1, 93-101 (2002).
5. R. R. de Fonseca, W. E. Johnson, S. J. O'Brien, et al., BMC Evol. Biol., 10, 281 (2010).
6. S. Goto, T. Iida, S. Cho, et al., Free Radic. Res., 31, No. 6, 549-558 (1999).
7. W. H. Habig, M. J. Pabst, and W. B. Jakoby, J. Biol. Chem., 249, No. 22, 7130-7139 (1974).
8. J. D. Hayes, J. U. Flanagan, I. R. Jowsey, Annu. Rev. Pharmacol. Toxicol., 45, 51-88 (2005).
9. A. Miyajima, J. Nakashima, K. Yoshioka, et al., Br. J. Cancer., 76, No. 2, 206-210 (1997).
10. F. Morel and C. Aninat, Drug Metab. Rev., 43, No. 2, 281-291 (2011).
11. C. Peklak-Scott, P. K. Smitherman, A. J. Townsend, and C. S. Morrow, Mol. Cancer Ther., 7, No. 10, 3247-3255 (2008).
12. H. Raza, FEBS J., 278, No. 22, 4243-4251 (2011).
13. H. Raza and A. John, Toxicol. Appl. Pharmacol., 216, No. 2, 309-318 (2006).
14. S. S. Singhal, M. Saxena, H. Ahmad, et al., Arch. Biochem. Biophys., 299, No. 2, 232-241 (1992).
15. G. Wang, E. Reed, and Q. Q. Li, Oncol. Rep., 12, No. 5, 955-965 (2004).